|Day Low/High||31.36 / 31.73|
|52 Wk Low/High||28.25 / 37.39|
Chevron and Pfizer will not just be big yielders in 2017, but big winners too, says Morgan Stanley's Dan Skelly.
Collaboration combines IBM Watson's cognitive computing capabilities with Pfizer's scientific knowledge to help scientists generate meaningful insights
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on...
Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to...
New Interoperability Is Designed to Streamline Clinical Workflow
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
Each dividend stock scores well for safety and has a historically high dividend yield.
Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint.
A Brazilian plane crash near Medellín on Monday included 21 journalists, among the largest number of media personnel to die in any one incident.
Stocks climbed as evidence of an economy on the mend overshadowed a slump in crude oil prices.
Wall Street ended just shy of records on Tuesday as a collapse in crude oil prices limited upward momentum.
Shares of Pfizer were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight
Stocks climb on Tuesday as evidence of an economy on the mend overshadows a slump in crude oil prices.
Market should still be able to breathe once central-bank prop is removed.
Pfizer's (PFE) stock rating at Barclays was upgraded to 'overweight' earlier today.
Stocks move higher on Tuesday morning, shaking off earlier losses driven by a slump in crude oil.
A new period of accumulation and sideways price action is likely needed before any upside movess.
Stock futures hold higher on Tuesday morning, unperturbed by a sharp decline in crude oil prices, as the U.S. economy grows at a faster-than-expected pace over the third quarter.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
Pfizer Inc. (NYSE:PFE) today announced that Anthony J.
Pfizer Inc. (NYSE:PFE) (the " Company") today announced the expiration and results of the previously announced tender offer (the " Tender Offer") to purchase for cash any and all of its outstanding 6.
Pfizer Inc. (NYSE:PFE) (the " Company") today announced the pricing of the previously announced tender offer (the " Tender Offer") to purchase for cash any and all of its outstanding 6.
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
Pfizer Inc. (NYSE:PFE) today announced that detailed results from the Phase 3 PALOMA-2 trial were published in The New England Journal of Medicine.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #13 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #260 spot.